The company's consistent loss and lack of revenue growth ove...
The company's consistent loss and lack of revenue growth over the past five years make it an unattractive investment. However, contrarian investors might want to research the stock in hope of a turnaround.
Further Weakness as Realcan Pharmaceutical Group (SZSE:002589) Drops 12% This Week, Taking Five-year Losses to 60%
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment